loading page

Role of transumbilical laparoendoscopic single-site surgery in the implementation of ERAS in gynecology oncology: a retrospective study
  • +3
  • Fanlin Li,
  • Ying Zheng,
  • Fan Yang,
  • Sijing Chen,
  • Qiao Wang,
  • Kana Wang
Ying Zheng

Corresponding Author:[email protected]

Author Profile
Sijing Chen
Author Profile

Abstract

Abstract: Objective: We accumulated the data to verify the fast recovery effect of transumbilical laparoendoscopic single-site surgery by analyzing the perioperative outcomes of patients with gynecological malignancies in the implementation of ERAS. Design: A retrospective study Setting: A university academic hospital Population or Sample: Patients with gynecological cancer undergoing transumbilical laparoendoscopic single-site surgery (TU-LESS) by a single experienced surgeon. Methods: This was a retrospective consecutive single-center study of patients with gynecological cancer undergoing TU-LESS from November 2017 and January 2022. Main Outcome Measures: The main outcomes were the perioperative outcomes in various surgeries including surgery time, estimated blood loss, length of hospital stay, and complications. Results: 315 gynecologic malignant cases successfully experienced TU-LESS in West China Second Hospital were incorporated, including 195 cervical cancers, 86 endometrial cancers and 34 ovarian cancers. The average age for patients is 47.48 (SD = 8.77). The average operating time and blood loss is 273.71 (SD = 87.12) minutes and 166.87 (SD = 237.09) ml, respectively. The average time for the first passage of flatus is 43.68 (SD = 29.75) hours. The hospitalization is 5.30 (SD = 2.42) days in average. Conclusions: TU-LESS is capable to enhance the recovery of patients who suffer from gynecological malignancies in the implementation of ERAS with less pain, shorter hospitalization and better rehabilitation. Funding: Science and Technology Program of Sichuan, China (2021YJ0137), Machine learning for risk warning and treatment guidance of preserving fertility in patients with endometrial cancer and endometrial atypical hyperplasia. Keywords: ERAS, TU-LESS, gynecology oncology